Jamie L. Koprivnikar

Oncology | Hematology
92 2nd Street
Hackensack, NJ 7601.

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.

Journal: Hematology (Amsterdam, Netherlands)
Published: December 12, 2024

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

Journal: Cancers
Published: January 05, 2024

Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report.

Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report.

Journal: Advances in therapy
Published: July 06, 2023

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Journal: Blood advances
Published: June 12, 2023

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.

Journal: Blood
Published: May 06, 2022

Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.

Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.

Journal: Frontiers in oncology
Published: April 19, 2022

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

Journal: Blood
Published: August 25, 2020

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

Journal: Blood advances
Published: January 10, 2020

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.

Journal: OncoTargets and therapy
Published: March 24, 2017

Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.

Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.

Journal: Future oncology (London, England)
Published: April 21, 2012
Showing 1-10 of 10

Last Updated: 09/26/2026